Breaking News Instant updates and real-time market news.

XLP

Consumer Staples Sector SPDR

$63.42 /

-0.43 (-0.67%)

08:22
08/12/20
08/12
08:22
08/12/20
08:22

Consumer Staples Sector SPDR: Pivot points

The following are the pivot points for the Consumer Staples Sector SPDR (XLP). Pivot High: $63.85, Pivot Low: $62.77. These were calculated using the DeMark method. It is generally believed to be bullish when price breaks out above the pivot high or bearish when price breaks down below the pivot low.

XLP Consumer Staples Sector SPDR
$63.42 /

-0.43 (-0.67%)

10/23/19 Morgan Stanley
Procter & Gamble results could bode well for Walmart, says Morgan Stanley

TODAY'S FREE FLY STORIES

Hot Stocks
MacroGenics presents MGD019 Phase 1 data at ESMO » 20:05
09/20/20
09/20
20:05
09/20/20
20:05
MGNX

MacroGenics

$31.61 /

+0.33 (+1.05%)

MacroGenics has announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MGNX MacroGenics
$31.61 /

+0.33 (+1.05%)

MGNX MacroGenics
$31.61 /

+0.33 (+1.05%)

08/03/20 Citi
MacroGenics downgraded to Neutral from Buy at Citi
06/02/20 Citi
MacroGenics price target raised to $25 from $15 at Citi
06/01/20 Guggenheim
Guggenheim upgrades MacroGenics to Buy on pipeline prospects
06/01/20 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
MGNX MacroGenics
$31.61 /

+0.33 (+1.05%)

MGNX MacroGenics
$31.61 /

+0.33 (+1.05%)

Hot Stocks
Phase 1 cohort of sotorasib data published in New England Journal of Medicine » 20:02
09/20/20
09/20
20:02
09/20/20
20:02
AMGN

Amgen

$248.01 /

-0.22 (-0.09%)

Amgen has announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

17:14 Today Piper Sandler
Amgen's sotorasib update 'Incrementally positive,' says Piper Sandler
09/18/20 Piper Sandler
Amgen sotosarib Phase 1 data a good news/bad news event, says Piper Sandler
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

Hot Stocks
Blueprint Medicines reports ARROW trial data at ESMO » 19:59
09/20/20
09/20
19:59
09/20/20
19:59
BPMC

Blueprint Medicines

$79.49 /

+1.29 (+1.65%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Blueprint Medicines…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BPMC Blueprint Medicines
$79.49 /

+1.29 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

BPMC Blueprint Medicines
$79.49 /

+1.29 (+1.65%)

09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
09/07/20 Piper Sandler
Early approval of Blueprint's Gavreto 'a nice surprise,' says Piper Sandler
07/15/20 Deutsche Bank
Blueprint Medicines price target raised to $95 from $85 at Deutsche Bank
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
RHHBY Roche
$0.00 /

+ (+0.00%)

09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
08/18/20 Morgan Stanley
Roche price target raised to CHF 372 from CHF 370 at Morgan Stanley
07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
BPMC Blueprint Medicines
$79.49 /

+1.29 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

  • 23
    Jan
RHHBY Roche
$0.00 /

+ (+0.00%)

BPMC Blueprint Medicines
$79.49 /

+1.29 (+1.65%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Chi-Med highlights surufatinib Phase 3 results in neuroendocrine tumors at ESMO » 19:56
09/20/20
09/20
19:56
09/20/20
19:56
HCM

Hutchison China MediTech

$34.29 /

+0.3 (+0.88%)

Hutchison China MediTech…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
HCM Hutchison China MediTech
$34.29 /

+0.3 (+0.88%)

HCM Hutchison China MediTech
$34.29 /

+0.3 (+0.88%)

03/13/20
Fly Intel: Top analyst initiations
03/12/20 Cantor Fitzgerald
Hutchison China MediTech initiated with an Overweight at Cantor Fitzgerald
02/20/20
Fly Intel: Top five analyst initiations
02/20/20 Goldman Sachs
Hutchison China MediTech initiated with a Buy at Goldman Sachs
HCM Hutchison China MediTech
$34.29 /

+0.3 (+0.88%)

  • 23
    Jan
Hot Stocks
Merck, Eisai present data from two studies evaluating KEYTRUDA plus LENVIMA » 19:53
09/20/20
09/20
19:53
09/20/20
19:53
MRK

Merck

$85.82 /

+0.17 (+0.20%)

Merck, known as MSD…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

Hot Stocks
Oracle, Walmart announce tentative U.S. government approval » 19:50
09/20/20
09/20
19:50
09/20/20
19:50
WMT

Walmart

$135.30 /

-1.39 (-1.02%)

, ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

The President has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Hot Stocks
Oracle chosen as TikTok's secure cloud provider » 19:47
09/20/20
09/20
19:47
09/20/20
19:47
ZM

Zoom Video

$439.00 /

+25.99 (+6.29%)

, ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

Oracle (ORCL) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ZM Zoom Video
$439.00 /

+25.99 (+6.29%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ZM Zoom Video
$439.00 /

+25.99 (+6.29%)

09/14/20 Baird
Zoom Video still in early innings of market penetration, says Baird
09/03/20 Needham
Crowdstrike price target raised to $170 from $120 at Needham
09/03/20 Stifel
Crowdstrike price target raised to $145 from $125 at Stifel
09/03/20 JMP Securities
Crowdstrike price target raised to $160 from $130 at JMP Securities
ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
ZM Zoom Video
$439.00 /

+25.99 (+6.29%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ZM Zoom Video
$439.00 /

+25.99 (+6.29%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ZM Zoom Video
$439.00 /

+25.99 (+6.29%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ZM Zoom Video
$439.00 /

+25.99 (+6.29%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Hot Stocks
Boeing announces order for two 737-800 Boeing Converted Freighters » 18:31
09/20/20
09/20
18:31
09/20/20
18:31
BA

Boeing

$161.07 /

-6.46 (-3.86%)

Boeing has announced a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

09/10/20 Susquehanna
Boeing 737 MAX making progress, but estimates lowered at Susquehanna
09/09/20 Canaccord
Boeing downside risk to production plans seen, says Canaccord
09/08/20
Fly Intel: Top five analyst initiations
09/08/20 Morgan Stanley
Boeing initiated with an Underweight at Morgan Stanley
BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

BA Boeing
$161.07 /

-6.46 (-3.86%)

Recommendations
Amgen's sotorasib update 'Incrementally positive,' says Piper Sandler » 17:14
09/20/20
09/20
17:14
09/20/20
17:14
AMGN

Amgen

$248.01 /

-0.22 (-0.09%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond remain Overweight rated on Amgen shares, with a $270 price target, and believes investors are likely to cheer updated ESMO data from sotorasib's Phase 1 study in KRAS-G12C mutant NSCLC. With mDOR almost 11 months, mPFS at 6.3 months and ORR at 35%, Raymond thinks if the potentially pivotal Phase 2 study produces similar results, Amgen will have a fileable monotherapy data package this year. Additionally, with a relatively clean safety profile, sotorasib remains well positioned to be evaluated as a combo therapy in KRAS-G12C mutant NSCLC and CRC settings, he adds. While Phase 2 NSCLC results remain on track to be presented before year-end, the analyst continues to wait for these data before modeling the sotorasib opportunity.

ShowHide Related Items >><<
AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

09/18/20 Piper Sandler
Amgen sotosarib Phase 1 data a good news/bad news event, says Piper Sandler
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 SVB Leerink
Amgen price target raised to $261 from $253 at SVB Leerink
AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

AMGN Amgen
$248.01 /

-0.22 (-0.09%)

On The Fly
Box Office Battle: ‘Tenet' stays on top, crosses $250M globally » 16:28
09/20/20
09/20
16:28
09/20/20
16:28
T

AT&T

$28.92 /

-0.16 (-0.55%)

, CMCSA

Comcast

$45.26 /

-0.35 (-0.77%)

, CMCSK

Comcast

$0.00 /

+ (+0.00%)

, SNE

Sony

$78.99 /

+1.44 (+1.86%)

, LGF.A

Lionsgate

$10.41 /

+0.035 (+0.34%)

, LGF.B

Lionsgate

$9.62 /

+0.05 (+0.52%)

, DIS

Disney

$128.66 /

-1.49 (-1.14%)

, VIACA

ViacomCBS

$33.03 /

+0.18 (+0.55%)

, VIAC

ViacomCBS

$30.16 /

-0.1 (-0.33%)

"Box Office Battle" is…

ShowHide Related Items >><<
VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSK Comcast
$0.00 /

+ (+0.00%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

T AT&T
$28.92 /

-0.16 (-0.55%)

08/31/20
Fly Intel: Top five analyst downgrades
08/31/20 Scotiabank
Scotiabank downgrades AT&T to Underperform on spectrum costs, share losses
08/31/20 Scotiabank
AT&T downgraded to Underperform from Sector Perform at Scotiabank
07/24/20 RBC Capital
AT&T price target lowered to $32 from $38 at RBC Capital
CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

09/18/20 Rosenblatt
Rosenblatt would be buyer on any Roku weakness amid latest Comcast 'tiff'
09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
08/24/20 BWS Financial
Xperi initiated with a Buy at BWS Financial
08/03/20 Deutsche Bank
Comcast price target raised to $53 from $47 at Deutsche Bank
CMCSK Comcast
$0.00 /

+ (+0.00%)

07/01/20
Fly Intel: Top five analyst upgrades
04/28/20 Wells Fargo
SeaWorld price target lowered to $16 from $36 at Wells Fargo
04/17/20 Oppenheimer
Comcast downgraded to Perform from Outperform at Oppenheimer
SNE Sony
$78.99 /

+1.44 (+1.86%)

08/17/20
Loeb's Third Point buys Alibaba, makes a top holding, during second quarter
08/05/20 Oppenheimer
Sony price target raised to $100 from $70 at Oppenheimer
07/30/20
Fly Intel: Top five analyst initiations
07/29/20 Goldman Sachs
Sony resumed with a Conviction Buy at Goldman Sachs
LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

09/02/20 Barrington
Lionsgate price target raised to $14 from $10 at Barrington
08/18/20 Barrington
Lionsgate upside 'may be achievable' says Barrington
07/13/20 Goldman Sachs
Lionsgate initiated with a Neutral at Goldman Sachs
06/18/20 Cowen
Lionsgate remain underappreciated OTT play, says Cowen
LGF.B Lionsgate
$9.62 /

+0.05 (+0.52%)

05/05/20 Canaccord
Lionsgate price target lowered to $13 from $16 at Canaccord
02/10/20 Truist
Lionsgate price target lowered to $15 from $18 at SunTrust
01/21/20 Wells Fargo
Lionsgate downgraded to Equal Weight from Overweight at Wells Fargo
DIS Disney
$128.66 /

-1.49 (-1.14%)

09/14/20 Jefferies
ESPN deal positive for both Caesars and DraftKings, says Jefferies
09/14/20 Evercore ISI
ESPN deal could add up to material dollars for DraftKings, says Evercore
09/08/20
Fly Intel: Top five analyst upgrades
09/08/20 Deutsche Bank
Disney upgraded to Buy from Hold at Deutsche Bank
VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

07/13/20
Fly Intel: Top five analyst initiations
07/13/20
Fly Intel: Top five analyst downgrades
04/07/20 Barrington
ViacomCBS downgraded to Market Perform from Outperform at Barrington
VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

09/02/20 Barrington
ViacomCBS price target raised to $32 from $30 at Barrington
08/27/20
Fly Intel: Top five analyst upgrades
08/27/20 Wells Fargo
ViacomCBS upgraded to Equal Weight from Underweight at Wells Fargo
08/27/20 Wells Fargo
ViacomCBS upgraded to Equal Weight from Underweight at Wells Fargo
VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSK Comcast
$0.00 /

+ (+0.00%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

LGF.A Lionsgate
$10.41 /

+0.035 (+0.34%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

VIACA ViacomCBS
$33.03 /

+0.18 (+0.55%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

VIAC ViacomCBS
$30.16 /

-0.1 (-0.33%)

T AT&T
$28.92 /

-0.16 (-0.55%)

SNE Sony
$78.99 /

+1.44 (+1.86%)

DIS Disney
$128.66 /

-1.49 (-1.14%)

CMCSA Comcast
$45.26 /

-0.35 (-0.77%)

Periodicals
Six charged with bribing Amazon employees to boost third-party sellers, WSJ says » 16:12
09/20/20
09/20
16:12
09/20/20
16:12
AMZN

Amazon.com

$2,953.50 /

-55.17 (-1.83%)

A federal grand jury in…

A federal grand jury in Washington state has indicted six people on charges of bribing Amazon.com employees to gain advantages for third-party sellers on the e-retailer's online storefront, where its business practices have drawn increased regulatory scrutiny, The Wall Street Journal's Matt Grossman reports. Reference Link

ShowHide Related Items >><<
AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

09/18/20 RBC Capital
Amazon.com's logistics network underappreciated by investors, says RBC Capital
09/16/20 Morgan Stanley
FedEx price target raised to $250 from $110 at Morgan Stanley
09/08/20 Goldman Sachs
Goldman sticks with Sell on Apple despite 71% rally since downgrade
09/03/20 Baird
Amazon working to better handle unprecedented seasonal Q4 demand, says Baird
AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

AMZN Amazon.com
$2,953.50 /

-55.17 (-1.83%)

Periodicals
TikTok owner seeking $60B valuation in U.S. deal, Bloomberg reports » 16:08
09/20/20
09/20
16:08
09/20/20
16:08
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

China's ByteDance is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Periodicals
China has reasons to like Tiktok's Trump-approved deal, WSJ reports » 15:58
09/20/20
09/20
15:58
09/20/20
15:58
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

A White House-approved…

A White House-approved plan to transform TikTok into a U.S.-based company would keep the operation of the viral short-video app, and likely the algorithm that has powered its rise, in Chinese hands, improving the deal's chances of finding favor in Beijing, which had threatened to veto a sale, The Wall Street Journal's Liza Lin reports. ByteDance's 80% stake in TikTok would allay fears in Beijing that the White House was forcing China to relinquish one of the world's hottest technology properties-or face a ban in the critical U.S. market, the author notes. Reference Link

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Periodicals
Tiktok deal facing questions over security, ownership, WSJ reports » 15:58
09/20/20
09/20
15:58
09/20/20
15:58
ORCL

Oracle

$59.77 /

-0.43 (-0.71%)

, WMT

Walmart

$135.30 /

-1.39 (-1.02%)

President Trump agreed in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

09/14/20 Wells Fargo
Oracle deal with TikTok looks like 'win-win,' says Wells Fargo
09/11/20 Societe Generale
Oracle price target raised to $70 from $60 at Societe Generale
09/11/20 RBC Capital
Oracle price target raised to $60 from $51 at RBC Capital
09/11/20 BMO Capital
Oracle price target raised to $63 from $57 at BMO Capital
WMT Walmart
$135.30 /

-1.39 (-1.02%)

09/18/20 Cleveland Research
Walmart U.S. sales appear directionally better recently, says Cleveland Research
09/03/20 KeyBanc
Inovalon price target raised to $29 from $24 at KeyBanc
09/03/20 Bernstein
Walmart+ 'a bit rushed,' Walmart still best deal on grocery, says Bernstein
09/02/20 Morgan Stanley
Oak Street deal with Walmart an incremental opportunity, says Morgan Stanley
WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

WMT Walmart
$135.30 /

-1.39 (-1.02%)

ORCL Oracle
$59.77 /

-0.43 (-0.71%)

Conference/Events
UBS consumer goods analyst to hold an analyst/industry conference call » 15:22
09/20/20
09/20
15:22
09/20/20
15:22
NKE

Nike

$114.63 /

-1.73 (-1.49%)

Consumer Analyst Sole,…

Consumer Analyst Sole, along with the former Finish Line CEO, Sam Sato, provide an update on Nike on an Analyst/Industry conference call to be held on September 23 at 12 pm.

ShowHide Related Items >><<
NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

09/18/20 Needham
Nike price target raised to $132 from $113 at Needham
09/18/20 Morgan Stanley
Nike price target raised to $142 from $121 at Morgan Stanley
09/18/20 Raymond James
Nike price target raised to $121 from $115 at Raymond James
09/18/20 Barclays
Nike price target raised to $132 from $118 at Barclays
NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

NKE Nike
$114.63 /

-1.73 (-1.49%)

Conference/Events
UBS healthcare analysts to hold an analyst/industry conference call » 15:19
09/20/20
09/20
15:19
09/20/20
15:19

Healthcare Analysts Mayo,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Express participates in a conference call with Cowen » 15:10
09/20/20
09/20
15:10
09/20/20
15:10
EXPR

Express

$0.91 /

-0.0604 (-6.23%)

Cowen Retail Analyst Chen…

Cowen Retail Analyst Chen holds a conference call with CEO Baxter who provides a preview of the Company's fall assortment and a holiday update on September 24 at 11 am. Webcast Link

ShowHide Related Items >><<
EXPR Express
$0.91 /

-0.0604 (-6.23%)

EXPR Express
$0.91 /

-0.0604 (-6.23%)

01/27/20 B. Riley FBR
Express price target raised to $4.50 from $4 at B. Riley FBR
01/22/20 Wedbush
Wedbush 'incrementally positive' on Express following strategic update
EXPR Express
$0.91 /

-0.0604 (-6.23%)

EXPR Express
$0.91 /

-0.0604 (-6.23%)

Conference/Events
Cardiff Oncology to hold a KOL conference call » 15:05
09/20/20
09/20
15:05
09/20/20
15:05
CRDF

Cardiff Oncology

$8.69 /

+0.58 (+7.15%)

Management holds a Key…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

09/18/20 Maxim
Cardiff Oncology price target raised to $14 from $6 at Maxim
CRDF Cardiff Oncology
$8.69 /

+0.58 (+7.15%)

Conference/Events
Sarepta to hold a conference call » 14:56
09/20/20
09/20
14:56
09/20/20
14:56
SRPT

Sarepta

$144.60 /

+0.62 (+0.43%)

Management discuss…

Management discuss long-term functional data from the Company's gene therapy programs on a conference call to be held on September 28 at 8:30 am. Webcast Link

ShowHide Related Items >><<
SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

09/15/20 Citi
Sarepta price target raised to $190 from $177 at Citi
09/10/20 Piper Sandler
Sarepta filing for SRP-9001 could still meet expectations, says Piper Sandler
09/10/20 Mizuho
Sarepta potential study delay 'largely immaterial,' says Mizuho
09/10/20 Goldman Sachs
Sarepta Phase 3 timelines 'could remain intact,' says Goldman Sachs
SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

SRPT Sarepta
$144.60 /

+0.62 (+0.43%)

Hot Stocks
Analysis shows AstraZeneca Tagrisso demonstrated improvement in CNS DFS » 14:52
09/20/20
09/20
14:52
09/20/20
14:52
AZN

AstraZeneca

$56.47 /

+0.53 (+0.95%)

Results from a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

09/18/20 Societe Generale
Societe Generale ups AstraZeneca target, sees earnings tripling in five years
09/09/20 Piper Sandler
Piper sees 'no readthrough' to Altimmune from AstraZeneca COVID trial hold
09/09/20 SVB Leerink
AstraZeneca pause 'a mixed blessing for Moderna, others, says SVB Leerink
09/09/20 SVB Leerink
AstraZeneca COVID vaccine hold may cause ripple, says SVB Leerink
AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

AZN AstraZeneca
$56.47 /

+0.53 (+0.95%)

Conference/Events
Merck to hold an investor briefing » 14:52
09/20/20
09/20
14:52
09/20/20
14:52
MRK

Merck

$85.82 /

+0.17 (+0.20%)

Management provides an…

Management provides an investor briefing on the company's broad oncology presentation at ESMO 2020 on a conference call to be held on September 22 at 8 am. Webcast Link

ShowHide Related Items >><<
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

Hot Stocks
Bristol-Myers, Exelixis announce results from Phase 3 CheckMate -9ER trial » 14:45
09/20/20
09/20
14:45
09/20/20
14:45
EXEL

Exelixis

$26.78 /

-0.16 (-0.59%)

, BMY

Bristol-Myers

$59.26 /

-0.14 (-0.24%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Bristol Myers Squibb…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
08/03/20 Credit Suisse
Ipsen price target raised to EUR 86 from EUR 69 at Credit Suisse
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

Hot Stocks
Ipsen announces results from Phase III CheckMate -9ER trial » 14:37
09/20/20
09/20
14:37
09/20/20
14:37
EXEL

Exelixis

$26.78 /

-0.16 (-0.59%)

, BMY

Bristol-Myers

$59.26 /

-0.14 (-0.24%)

, IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Ipsen (IPSEY) announced…

Ipsen (IPSEY) announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx in combination with Bristol Myers Squibb's (BMY) Opdivo demonstrated "significant improvements" across all efficacy endpoints, including overall survival, in previously untreated advanced renal cell carcinoma. Cabometyx in combination with Opdivo reduced the risk of death by 40% versus sunitinib. In patients receiving Cabometyx in combination with Opdivo, median progression-free survival, the trial's primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively. In addition, Cabometyx in combination with Opdivo demonstrated a superior objective response rate, with twice as many patients responding compared to sunitinib, and 8% versus 5% achieved a complete response. Cabometyx in combination with Opdivo was associated with a longer duration of response than sunitinib, with a median duration of 20.2 months versus 11.5 months. Additionally, patients treated with the combination had a much lower rate of treatment discontinuation versus sunitinib, and a significantly lower rate of treatment discontinuation due to disease progression versus sunitinib. All key efficacy results were consistent across the pre-specified International Metastatic Renal Cell Carcinoma Database Consortium risk and PD-L1 subgroups. Cabometyx in combination with Opdivo was well tolerated and reflected the known safety profiles of the immunotherapy and tyrosine kinase inhibitor components in previously untreated advanced RCC. The incidence of treatment-related adverse events, including any-grade and high- grade TRAEs, was slightly higher for Cabometyx in combination with Opdivo versus sunitinib, with a low rate of treatment- related discontinuations. Patients treated with Cabometyx in combination with Opdivo reported significantly better health-related quality of life than those treated with sunitinib at most time points, according to National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 scores. Based on these efficacy and safety results from CheckMate -9ER, Ipsen and Bristol Myers Squibb have each submitted type II variation applications for Cabometyx in combination with Opdivo to the European Medicines Agency. On September 12, the EMA validated the type II variations, confirming the submissions are complete and beginning the EMA's centralized review process. In addition, Bristol Myers Squibb and Exelixis (EXEL), which has exclusive rights to commercialize and develop Cabometyx in the U.S., recently completed their respective U.S. FDA submissions for Cabometyx in combination with Opdivo and for Opdivo in combination with Cabometyx, and along with their partners, they plan to discuss the CheckMate -9ER data with regulatory authorities across the world.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
05/14/20 Truist
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

08/25/20 Piper Sandler
Bristol's trial miss has 'no financial impact' on Agios, says Piper Sandler
08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
08/03/20 Credit Suisse
Ipsen price target raised to EUR 86 from EUR 69 at Credit Suisse
EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

EXEL Exelixis
$26.78 /

-0.16 (-0.59%)

BMY Bristol-Myers
$59.26 /

-0.14 (-0.24%)

Hot Stocks
Genentech presents new data from multiple Phase III studies of Tecentriq in TNBC » 14:21
09/20/20
09/20
14:21
09/20/20
14:21
RHHBY

Roche

$0.00 /

+ (+0.00%)

Genentech, a member of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

09/09/20 Jefferies
ASH data could prompt 40% rise, or 70% drop, for IGM Biosciences, says Jefferies
08/18/20 Morgan Stanley
Roche price target raised to CHF 372 from CHF 370 at Morgan Stanley
07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Hot Stocks
Merck announces findings from Phase 3 EORTC1325/KEYNOTE-054 trial » 14:13
09/20/20
09/20
14:13
09/20/20
14:13
MRK

Merck

$85.82 /

+0.17 (+0.20%)

Merck, known as MSD…

Merck, known as MSD outside the United States and Canada, and the European Organisation for Research and Treatment of Cancer announced new and updated findings from the Phase 3 EORTC1325/KEYNOTE-054 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma. Late-breaking, first-time study results showed that with 3.5 years of follow-up, adjuvant KEYTRUDA met the key secondary endpoint of distant metastasis-free survival, reducing the risk of distant metastasis or death by 40% versus placebo, with 3.5-year DMFS rates of 65.3% and 49.4%, respectively. In addition, KEYTRUDA demonstrated a sustained recurrence-free survival benefit versus placebo across stage IIIA, IIIB and IIIC melanoma, with 3.5-year RFS rates of 59.8% for KEYTRUDA versus 41.4% for placebo. The RFS and DMFS benefits were observed across key subgroups, including disease stages, BRAF mutation status and PD-L1 expression. These late-breaking data were presented as a proffered paper at the European Society for Medical Oncology Virtual Congress 2020.

ShowHide Related Items >><<
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

09/15/20 SVB Leerink
Seattle Genetics price target raised to $185 from $173 at SVB Leerink
09/14/20 RBC Capital
Seattle Genetics price target raised to $191 from $175 at RBC Capital
09/14/20 Piper Sandler
Seattle Genetics price target raised to $172 from $165 at Piper Sandler
08/11/20 H.C. Wainwright
Pfenex acquisition fits well with Ligand growing portfolio, says H.C. Wainwright
MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

MRK Merck
$85.82 /

+0.17 (+0.20%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.